At #WCLC2025, patient advocate Debra Montague unveiled new survey data showing serious communication challenges in lung cancer care.
Full story in ILCN: https://bit.ly/48MyLD8
#LCSM
Full story in ILCN: https://bit.ly/48MyLD8
#LCSM
Lost in Translation: Survey Reveals Critical Communication Gaps in Lung Cancer Care - ILCN.org (ILCN/WCLC)
Complex information and poor communication were identified as major obstacles to meaningful participation in decision-making, according to data presented by patient advocate Debra Montague.
bit.ly
October 28, 2025 at 2:54 PM
At #WCLC2025, patient advocate Debra Montague unveiled new survey data showing serious communication challenges in lung cancer care.
Full story in ILCN: https://bit.ly/48MyLD8
#LCSM
Full story in ILCN: https://bit.ly/48MyLD8
#LCSM
🚨 Spotlight on Dr Tracy Leong at #WCLC2025!
She presented on EBUS & optimal staging for clinical N–N1 NSCLC, showing how minimally invasive diagnostics improve treatment planning & patient safety.
🗣️ “Collaboration and precision staging are key to improving outcomes for every patient.”
She presented on EBUS & optimal staging for clinical N–N1 NSCLC, showing how minimally invasive diagnostics improve treatment planning & patient safety.
🗣️ “Collaboration and precision staging are key to improving outcomes for every patient.”
September 24, 2025 at 11:00 PM
🚨 Spotlight on Dr Tracy Leong at #WCLC2025!
She presented on EBUS & optimal staging for clinical N–N1 NSCLC, showing how minimally invasive diagnostics improve treatment planning & patient safety.
🗣️ “Collaboration and precision staging are key to improving outcomes for every patient.”
She presented on EBUS & optimal staging for clinical N–N1 NSCLC, showing how minimally invasive diagnostics improve treatment planning & patient safety.
🗣️ “Collaboration and precision staging are key to improving outcomes for every patient.”
🚨 Exciting milestone! TRACKER PhD Candidate Dr Senthuran Shivakumar presented his first 2 posters at #WCLC2025 🎉 His research discovers biomarkers of checkpoint inhibitor pneumonitis to enable sustainable, high-quality survivorship.
September 19, 2025 at 7:00 AM
🚨 Exciting milestone! TRACKER PhD Candidate Dr Senthuran Shivakumar presented his first 2 posters at #WCLC2025 🎉 His research discovers biomarkers of checkpoint inhibitor pneumonitis to enable sustainable, high-quality survivorship.
IASLC - New Lung Cancer Considered from WCLC 2025
@iaslc.bsky.social @stephenvliu.bsky.social @narjustflorezmd.bsky.social
oncodaily.com/voices/lung-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC2025 #IASLC #LungCancer
@iaslc.bsky.social @stephenvliu.bsky.social @narjustflorezmd.bsky.social
oncodaily.com/voices/lung-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC2025 #IASLC #LungCancer
New Lung Cancer Considered from WCLC 2025 - IASLC - OncoDaily
New Lung Cancer Considered from WCLC 2025 - IASLC / cancer, IASLC, Narjust Florez, OncoDaily, Oncology, Stephen V Liu, WCLC 2025, WCLC2025
oncodaily.com
September 18, 2025 at 12:40 PM
IASLC - New Lung Cancer Considered from WCLC 2025
@iaslc.bsky.social @stephenvliu.bsky.social @narjustflorezmd.bsky.social
oncodaily.com/voices/lung-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC2025 #IASLC #LungCancer
@iaslc.bsky.social @stephenvliu.bsky.social @narjustflorezmd.bsky.social
oncodaily.com/voices/lung-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC2025 #IASLC #LungCancer
In metastatic EGFR-mutated non-small cell #LungCancer (#NSCLC), targeting residual disease through surgery can extend the benefits of #EGFR TKI therapy beyond standard monotherapy, a new study presented at the @iaslc.bsky.social #WCLC2025 finds.
September 18, 2025 at 6:30 AM
In metastatic EGFR-mutated non-small cell #LungCancer (#NSCLC), targeting residual disease through surgery can extend the benefits of #EGFR TKI therapy beyond standard monotherapy, a new study presented at the @iaslc.bsky.social #WCLC2025 finds.
How does new evidence guide decisions in lung cancer care? Get the expert updates you need to know from #WCLC2025 on imaging tools, from emerging technologies to their evolving role in lung cancer staging, with our swipe through symposia summaries 🫁 #MedSky #CancerSky
ow.ly/ggtm50WXBjC
ow.ly/ggtm50WXBjC
September 16, 2025 at 3:21 PM
How does new evidence guide decisions in lung cancer care? Get the expert updates you need to know from #WCLC2025 on imaging tools, from emerging technologies to their evolving role in lung cancer staging, with our swipe through symposia summaries 🫁 #MedSky #CancerSky
ow.ly/ggtm50WXBjC
ow.ly/ggtm50WXBjC
Is it time to rethink lung cancer screening age limits?
New research shows older adults can benefit—if they’re fit enough for surgery.
@neilosterweil.bsky.social's latest for Medical News Insider from #WCLC2025: medicalnewsinsider.substack.com/p/to-screen-...
#PublicHealth #CancerCare
New research shows older adults can benefit—if they’re fit enough for surgery.
@neilosterweil.bsky.social's latest for Medical News Insider from #WCLC2025: medicalnewsinsider.substack.com/p/to-screen-...
#PublicHealth #CancerCare
To Screen, or Not to Screen? It’s A Question of Age
Older people found to have lung cancer through screening are more likely to die from any cause than their younger counterparts, but are just as likely to survive the disease following surgery.
medicalnewsinsider.substack.com
September 15, 2025 at 11:19 AM
Is it time to rethink lung cancer screening age limits?
New research shows older adults can benefit—if they’re fit enough for surgery.
@neilosterweil.bsky.social's latest for Medical News Insider from #WCLC2025: medicalnewsinsider.substack.com/p/to-screen-...
#PublicHealth #CancerCare
New research shows older adults can benefit—if they’re fit enough for surgery.
@neilosterweil.bsky.social's latest for Medical News Insider from #WCLC2025: medicalnewsinsider.substack.com/p/to-screen-...
#PublicHealth #CancerCare
What were the biggest research stories at #WCLC2025?
In this Mandarin episode of Lung Cancer Considered, Dr. Chunxia Su speaks with Dr. Yang Xia and Dr. Nan Bi about the most impactful findings from this year’s conference.
🎧 Listen here: bit.ly/3Il284D
#IASLC #LungCancer #WCLC2025 #Oncology
In this Mandarin episode of Lung Cancer Considered, Dr. Chunxia Su speaks with Dr. Yang Xia and Dr. Nan Bi about the most impactful findings from this year’s conference.
🎧 Listen here: bit.ly/3Il284D
#IASLC #LungCancer #WCLC2025 #Oncology
LCC in Mandarin: WCLC 2025 Highlights | IASLC
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer resear ...
bit.ly
September 12, 2025 at 8:17 PM
What were the biggest research stories at #WCLC2025?
In this Mandarin episode of Lung Cancer Considered, Dr. Chunxia Su speaks with Dr. Yang Xia and Dr. Nan Bi about the most impactful findings from this year’s conference.
🎧 Listen here: bit.ly/3Il284D
#IASLC #LungCancer #WCLC2025 #Oncology
In this Mandarin episode of Lung Cancer Considered, Dr. Chunxia Su speaks with Dr. Yang Xia and Dr. Nan Bi about the most impactful findings from this year’s conference.
🎧 Listen here: bit.ly/3Il284D
#IASLC #LungCancer #WCLC2025 #Oncology
🌍 At #WCLC2025, researchers revealed IFITM3 as a key driver of immunotherapy response in SCLC, boosting antigen presentation and T cell activity while emerging as a potential biomarker and target.
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer #Immunotherapy #WCLC
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer #Immunotherapy #WCLC
WCLC 2025: IFITM3 May Improve Immunotherapy Outcomes in SCLC
New research identifies IFITM3 as a driver of immunotherapy response in small cell lung cancer, improving MHC-I expression and CD8⁺ T cell activity, with potential as biomarker and target.
www.emjreviews.com
September 11, 2025 at 2:13 PM
🌍 At #WCLC2025, researchers revealed IFITM3 as a key driver of immunotherapy response in SCLC, boosting antigen presentation and T cell activity while emerging as a potential biomarker and target.
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer #Immunotherapy #WCLC
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer #Immunotherapy #WCLC
Issue #737 of The Imaging Wire is live:
- CT Lung Cancer Screening News from #WCLC2025
- CT Radiation Before Conception
- Faster MRI for Prostate Cancer
- MRI Predicts Aneurysm Rupture Risk
Read more at theimagingwire.com/newsletter/c....
#radiology #lungcancer
- CT Lung Cancer Screening News from #WCLC2025
- CT Radiation Before Conception
- Faster MRI for Prostate Cancer
- MRI Predicts Aneurysm Rupture Risk
Read more at theimagingwire.com/newsletter/c....
#radiology #lungcancer
CT Lung Screening, CT Radiation Effects, and GE to Buy icometrix - The Imaging Wire
CT lung screening news from WCLC 2025, CT radiation before conception, GE to buy icometrix, MRI predicts aneurysm rupture, and much more.
theimagingwire.com
September 11, 2025 at 1:50 PM
Issue #737 of The Imaging Wire is live:
- CT Lung Cancer Screening News from #WCLC2025
- CT Radiation Before Conception
- Faster MRI for Prostate Cancer
- MRI Predicts Aneurysm Rupture Risk
Read more at theimagingwire.com/newsletter/c....
#radiology #lungcancer
- CT Lung Cancer Screening News from #WCLC2025
- CT Radiation Before Conception
- Faster MRI for Prostate Cancer
- MRI Predicts Aneurysm Rupture Risk
Read more at theimagingwire.com/newsletter/c....
#radiology #lungcancer
The combination of tarlatamab (Imdelltra) and a PD-L1 inhibitor after first-line chemo-immunotherapy showed promise as a maintenance therapy in patients with ES-SCLC, with a manageable safety profile, according to the phase Ib DeLLphi-303 trial. #WCLC2025
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
'Unprecedented' Survival Seen With Maintenance Tarlatamab for SCLC in Early Study
'I know I'm supposed to be critical, but it's a wow,' one expert says
www.medpagetoday.com
September 10, 2025 at 8:25 PM
The combination of tarlatamab (Imdelltra) and a PD-L1 inhibitor after first-line chemo-immunotherapy showed promise as a maintenance therapy in patients with ES-SCLC, with a manageable safety profile, according to the phase Ib DeLLphi-303 trial. #WCLC2025
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
September 10, 2025 at 11:30 AM
At #WCLC2025, the NAUTIKA1 study showed the impact of giving alectinib before surgery in early-stage ALK+ #lungcancer:
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
September 9, 2025 at 5:19 PM
At #WCLC2025, the NAUTIKA1 study showed the impact of giving alectinib before surgery in early-stage ALK+ #lungcancer:
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
If you liked our coverage of #WCLC25, why not visit our expert resources for more of the latest updates in oncology? From podcasts to congress highlights, get closer to the conversations that matter with Medthority
#Oncology #MedX #WCLC2025
ow.ly/hgL450WTLcy
#Oncology #MedX #WCLC2025
ow.ly/hgL450WTLcy
September 9, 2025 at 10:48 AM
If you liked our coverage of #WCLC25, why not visit our expert resources for more of the latest updates in oncology? From podcasts to congress highlights, get closer to the conversations that matter with Medthority
#Oncology #MedX #WCLC2025
ow.ly/hgL450WTLcy
#Oncology #MedX #WCLC2025
ow.ly/hgL450WTLcy
That's it for our LIVE coverage of 'Challenging Scenarios for Immunotherapy Treatment' at #WCLC25 🫁 Chaired by
Thanyanan Baisamut & Tom John, speakers tackled tough cases from autoimmune disease to brain metastases & ICI rechallenge
#Oncology #MedX #IASLC #LungCancer #WCLC2025
Thanyanan Baisamut & Tom John, speakers tackled tough cases from autoimmune disease to brain metastases & ICI rechallenge
#Oncology #MedX #IASLC #LungCancer #WCLC2025
September 9, 2025 at 10:43 AM
Thomas John on immunotherapy in brain metastases at #WCLC25
🔹 CNS TME differs from extracranial sites
🔹 Most brain metastases generate immunosuppressive environments
🔹 Data shows combo immunotherapy responses are good but lack durability
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
🔹 CNS TME differs from extracranial sites
🔹 Most brain metastases generate immunosuppressive environments
🔹 Data shows combo immunotherapy responses are good but lack durability
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
September 9, 2025 at 10:15 AM
Latest on treating elderly frail patients with immunotherapy from Roberto Ferrara at #WCLC25
🔹 Elderly patients not included in pivotal trials
🔹 Biological age & immunosenescence may guide decisions better than chronological age
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
🔹 Elderly patients not included in pivotal trials
🔹 Biological age & immunosenescence may guide decisions better than chronological age
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
September 9, 2025 at 10:00 AM
Navigating immunotherapy in complex cases?
@nymurakami.bsky.social shares her insights at #WCLC25
🔹 AEs vary in tempo & severity
🔹 ICIs show efficacy but trial data lacking for these groups
🔹 Multidisciplinary monitoring is key
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
@nymurakami.bsky.social shares her insights at #WCLC25
🔹 AEs vary in tempo & severity
🔹 ICIs show efficacy but trial data lacking for these groups
🔹 Multidisciplinary monitoring is key
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
September 9, 2025 at 9:45 AM
Navigating immunotherapy in complex cases?
@nymurakami.bsky.social shares her insights at #WCLC25
🔹 AEs vary in tempo & severity
🔹 ICIs show efficacy but trial data lacking for these groups
🔹 Multidisciplinary monitoring is key
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
@nymurakami.bsky.social shares her insights at #WCLC25
🔹 AEs vary in tempo & severity
🔹 ICIs show efficacy but trial data lacking for these groups
🔹 Multidisciplinary monitoring is key
#Oncology #MedSky #IASLC #LungCancer #WCLC2025
1 hour to go! Stay tuned for expert insights from today’s 'Challenging Scenarios for Immunotherapy Treatment' symposium at #WCLC25. Follow along here for the live updates you need to know
#MedSky #LungCancer #WCLC2025 #IASLC
#MedSky #LungCancer #WCLC2025 #IASLC
September 9, 2025 at 8:31 AM
1 hour to go! Stay tuned for expert insights from today’s 'Challenging Scenarios for Immunotherapy Treatment' symposium at #WCLC25. Follow along here for the live updates you need to know
#MedSky #LungCancer #WCLC2025 #IASLC
#MedSky #LungCancer #WCLC2025 #IASLC
At #WCLC2025, Henlius shared data on HLX43, an anti-PD-L1 ADC, in advanced NSCLC. It showed a 37% ORR, 87% DCR, and 5.4-month mPFS across subgroups, including brain mets. Safety was manageable; irAEs linked to better outcomes. Results support further trials, including frontline use.
September 9, 2025 at 8:15 AM
At #WCLC2025, Henlius shared data on HLX43, an anti-PD-L1 ADC, in advanced NSCLC. It showed a 37% ORR, 87% DCR, and 5.4-month mPFS across subgroups, including brain mets. Safety was manageable; irAEs linked to better outcomes. Results support further trials, including frontline use.
🔵🫁 @aeacap.bsky.social ha asistido a la #WCLC2025 para conocer los últimos avances científicos y clínicos vinculados a la prevención, el diagnóstico y el tratamiento del #cáncerdepulmón
➡️ También se han expuesto los avances en terapias dirigidas y enfoques multidisciplinares
➡️ También se han expuesto los avances en terapias dirigidas y enfoques multidisciplinares
September 8, 2025 at 8:49 PM
🔵🫁 @aeacap.bsky.social ha asistido a la #WCLC2025 para conocer los últimos avances científicos y clínicos vinculados a la prevención, el diagnóstico y el tratamiento del #cáncerdepulmón
➡️ También se han expuesto los avances en terapias dirigidas y enfoques multidisciplinares
➡️ También se han expuesto los avances en terapias dirigidas y enfoques multidisciplinares